TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8230691
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg TNG solution (Solution group)
Study: 8230691
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg TNG spray (Spray group)
Study: 20220746
Drug: Acetaminophen-Placebo (AP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen-Placebo (AP)
Study: 20220746
Drug: Acetaminophen-Ondansetron (AO)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetaminophen-Ondansetron (AO)
Study: 18586925
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy (combined modality treatment)
Study: 11219367
Drug: Supervised injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised injectable methadone maintenance treatment (MMT)
Study: 25262567
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone maintenance treatment (MMT)
Study: 9379379
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% gel (Timoptic XE)
Study: 9379379
Drug: Oral, sustained‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, sustained‐release acetazolamide (Diamox Sequels)
Study: 1327628
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg followed by 25 mg 2 h later)
Study: 2427842
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 or 400 mg
Study: 2427842
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 or 80 mg
Study: 27053325
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/day for 10 days)
Study: 21095333
Drug: ACEi plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi plus β‐blockers (ramipril plus metoprolol)
Study: 18678789
Drug: Rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 0.5 mg daily
Study: 18678789
Drug: Rasagiline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1.0 mg daily
Study: 9598252
Drug: 0.1 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg.kg-1 rocuronium
Study: 9598252
Drug: 0.1 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg.kg-1 atracurium
Study: 9598252
Drug: 0.1 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml.kg-1 normal saline (placebo)
Study: 8181203
Drug: Computer-assisted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted heparin therapy
Study: 3119776
Drug: RX77368 (thyrotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX77368 (thyrotrophin releasing hormone analogue), iv over 2 hours
Study: 31933472
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg oral dose after 10 hours of fasting
Study: 31933472
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg oral dose 30 minutes after a high-fat meal
Study: 29327733
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance
Study: 15879357
Drug: Estrogen discontinuation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen discontinuation after 28 days
Study: 12578771
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) application during silicone intubation (SI) at 0.2 mg/ml for 2 minutes before SI
Study: 10475361
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus immediate androgen suppression (LHRH agonist)
Study: 26149129
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg/day
Study: 27206047
Drug: DOVE treatment
Normalized name: Dove DermaSeries
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOVE treatment group
Study: 18241321
Drug: XR‐NTX 380
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR‐NTX 380 mg
Study: 12385694
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g
Study: 2745258
Drug: Cefotetan 2
Normalized name: cefotetan 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 2 g
Study: 10856310
Drug: Air therapy
Normalized name: Amlactin Foot Repair Therapy 15% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air therapy (AT) at 4 l/min
Study: 10856310
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (OT) at baseline
Study: 9201614
Drug: Pippali Rasayana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pippali Rasayana (PR) administered at a dose of 1 g p.o. three times daily for 15 days
Study: 3857627
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion at 2 mg/kg of body weight per min
Study: 30465339
Drug: Universal adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal adhesive treatment for 30 s (adult teeth)
Study: 24130347
Drug: Antibiotics group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics group (AG) - treated exclusively with antibiotics for 90 days
Study: 24130347
Drug: Surgical group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical group (SG) - underwent conservative surgery with postoperative antibiotic treatment for 10 days
Study: 9500747
Drug: TAA aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA aqueous nasal spray 220 microg
Study: 9500747
Drug: TAA aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA aqueous nasal spray 440 microg
Study: 7544732
Drug: Casodex (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (50 mg daily for 24 weeks)
Study: 2653971
Drug: Calcitonin (415
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (415 pmol iv bolus followed by a 90 minute infusion to reach an overall dose of 62.25 pmol/kg)
Study: 2308759
Drug: Benzydamine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine 3% cream
Study: 12108813
Drug: Multisystemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy (MST)
Study: 20234144
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo after indomethacin administration)
Study: 15790982
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 2000 microg daily for 12 weeks
Study: 10429835
Drug: Zanamivir administered
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir administered by intravenous route (up to 600 mg)
Study: 10429835
Drug: Zanamivir administered
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir administered by oral route
Study: 10429835
Drug: Zanamivir administered
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir administered by intranasal route
Study: 10429835
Drug: Zanamivir administered
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir administered by inhaled route (nebuliser and dry powder)
Study: 7751495
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for depression (12 sessions)
Study: 393053
Drug: Bromocriptine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, 2.5 mg twice a day
Study: 16246656
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (800 mcg)
Study: 15491558
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (800 mcg)
Study: 11917285
Drug: Amifostine (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (340 mg/m2) plus RT
Study: 2675427
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg twice daily for two years or until death
Study: 341363
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 or 300 mg every 6 hours)
Study: 27823977
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)
Study: 23026548
Drug: BTDS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 10 mcg/hour patches applied for seven days
Study: 15374364
Drug: Idebenone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (45 mg twice daily orally)
Study: 30140327
Drug: Forced oscillation
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced oscillation technique (FOT) with 200 mcg salbutamol by MDI
Study: 25757036
Drug: SPORT surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPORT surgical treatment
Study: 25757036
Drug: NSQIP surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSQIP surgical treatment
Study: 14666760
Drug: Hydergine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine, 2 mg orally, 3 times a day for 2 months
Study: 30227969
Drug: Honey plus
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey plus oral acyclovir
Study: 27997586
Drug: Syntometrine® administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntometrine® administration
Study: 12581080
Drug: Topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 3% diclofenac in 2.5% hyaluronan gel
Study: 12581080
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle only, hyaluronan gel)
Study: 8501574
Drug: GBS hyperimmune
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS hyperimmune IVIG, 500 mg/kg
Study: 3326679
Drug: Controlled-release hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release hydralazine QD
Study: 3326679
Drug: Beta-blocker (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (80 mg/day of nadolol)
Study: 30742378
Drug: Nefradoz 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefradoz 1 capsule 2 times a day (n=45)
Study: 27784460
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment (cinobufacini injection, herbal decoction, and Chinese acupoint application)
Study: 25886416
Drug: Bupivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine group (3 mg bupivacaine + 10 ug fentanyl)
Study: 25886416
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (20 mg lidocaine + 25 ug fentanyl)
Study: 16682486
Drug: Western diet
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western diet supplemented with wheat bran (24 g/day)
Study: 4699595
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg betamethasone in saline
Study: 31188172
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 2 mL (8 mg) dexamethasone (Dexa)
Study: 31188172
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 2 mL (1 µg/kg) dexmedetomidine (Dexm)
Study: 28724657
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA; 60 mg Fe + 400 μg folic acid/d)
Study: 26458895
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily for 14 days
Study: 23977723
Drug: Butyrylated high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrylated high amylose maize starch (HAMSB) 20 g twice daily for 28 days
Study: 11350463
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg intravenously
Study: 18006188
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg intravenously
Study: 12951616
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UCA) 10 mg/kg/day until surgery, n=30
Study: 25828692
Drug: Etoricoxib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (120 mg pre-emptive administration)
Study: 25828692
Drug: Etoricoxib (post-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (post-operative treatment)
Study: 25828692
Drug: Placebo (post-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (post-operative treatment)
Study: 25436273
Drug: 8-week stress
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week stress management programme (diaphragmatic breathing, progressive muscle relaxation, guided imagery, twice a day)
Study: 10403354
Drug: Antibiotics (erythromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (erythromycin, doxycycline, trimethoprim/sulfamethoxazole)
Study: 7338577
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 to 2 mg daily for three days)
Study: 23876569
Drug: Meditation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditation therapy
Study: 19697195
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg natural micronised progesterone intravaginally once daily from 20‐24 weeks' gestation until 36 weeks
Study: 19697195
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg natural micronised progesterone intravaginally
Study: 29729588
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of fluoxetine
Study: 8480824
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of fluoxetine
Study: 18784099
Drug: Physical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical and medical therapy alone (Control)
Study: 18784099
Drug: Surgical lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical lavage and arthroscopic debridement together with optimized physical and medical therapy
Study: 22773282
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% glucose solution)
Study: 8767241
Drug: Etomidate (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (in lipid emulsion) 0.25 mg/kg
Study: 1443704
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kg
Study: 1897306
Drug: Regularly or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly or irregularly administered toxoid doses
Study: 6225405
Drug: Electroconvulsive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive treatment
Study: 27321067
Drug: Client‐centred activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client‐centred activity of daily living intervention (CADL)
Study: 22595038
Drug: donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil (5 mg q.d)
Study: 17428104
Drug: Oral satraplatin
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral satraplatin plus prednisone
Study: 8943507
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (90 mg vaginal progesterone per day)
Study: 8943507
Drug: Utrogestan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan (300 mg oral micronized progesterone)
Study: 1647293
Drug: Naloxone (0.5-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.5-1.0 mg, i.m.) administered at 6, 30 and 54 h after methadone pre-treatment
Study: 2072190
Drug: Oral triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral triazolam
Study: 19863477
Drug: Albiglutide 15
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albiglutide 15 mg weekly
Study: 19592625
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg weekly
Study: 12702897
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (500-2500 mg)
Study: 27306347
Drug: Ciprofloxacin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, amoxicillin, and omeprazole (CAO)
Study: 17356388
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) > or =90 mg/L
Study: 2659383
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 200 mg x 3 daily for patients <30 kg or 400 mg x 2 daily for patients >30 kg
Study: 19168019
Drug: Oral lyophilisate
Normalized name: ORAL LYOPHILISATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lyophilisate (Minirinmelt)
Study: 19168019
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (lyophilisate and tablet)
Study: 17360873
Drug: Tafenoquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (200 mg base/day for 3 days, followed by 200 mg/week for 8 weeks)
Study: 28677349
Drug: HBB 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBB 20 mg
Study: 7857751
Drug: ACE-inhibitor (enalapril)
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor (enalapril) added to conventional heart failure therapy
Study: 11719353
Drug: G-PBSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-PBSC
Study: 17315706
Drug: Levitra (vardenafil;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levitra (vardenafil; 5 mg per os each other day)
Study: 2764545
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 1,000 mg
Study: 2764545
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 1,500 mg
Study: 2764545
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 2,000 mg
Study: 18768245
Drug: Magnesium (360mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (360mg daily)
Study: 10665553
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (target international normalised ratio 3.0‐4.5, n=1339)
Study: 10665553
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg daily, n=1351)
Study: 27115063
Drug: Fortified bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified bread (FP; 50 g bread fortified with 25 μg vitamin D3 plus placebo daily; n = 30)
Study: 27115063
Drug: Supplement (SP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (SP; 50 g plain bread plus 25 μg vitamin D supplement daily; n = 30)
Study: 27115063
Drug: Control (CP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CP; 50 g plain bread plus placebo daily; n = 30)
Study: 24650128
Drug: High fibre
Normalized name: Adult high protein high fibre formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fibre supplement (HFS)
Study: 15862926
Drug: Intravenous sodium-lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium-lactate infusion
Study: 10337463
Drug: Anti-IFN alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IFN alpha vaccine
Study: 31523872
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs measured
Study: 31523872
Drug: Baseline drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline drug use
Study: 28245970
Drug: rAAV.sFlt‐1 subretinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV.sFlt‐1 subretinal injection (low-dose: 1 × 10^10 vector genomes; high-dose: 1 × 10^11 vector genomes)
Study: 24714414
Drug: H.P. Acthar(®)
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H.P. Acthar(®) Gel (40 or 80 IU subcutaneously twice weekly)
Study: 24714414
Drug: H.P. Acthar(®)
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H.P. Acthar(®) Gel
Study: 17259872
Drug: HA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 1 at ages 6 and 12 months
Study: 17259872
Drug: HA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 1 (6 and 12 months) vs group 3 (15 and 21 months)
Study: 17259872
Drug: Routine vaccinations
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine vaccinations administered during infancy
Study: 11449083
Drug: 28.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28.5 mg/day of isoflavones
Study: 11449083
Drug: 57 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57 mg/day of isoflavones
Study: 11449083
Drug: 85.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85.5 mg/day of isoflavones
Study: 11449083
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of isoflavones
Study: 2977262
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg Zoladex depot subcutaneous injection every 28 days for 12 weeks